Liquid Biopsy to Identify Biomarkers for Immunotherapy in Hepatocellular Carcinoma

Overview

Journal Biomark Res

Publisher Biomed Central

Date 2021 Dec 21

PMID 34930486

Citations 10

Authors

Huang Ao

Zhang Xin

Zhou Jian

Affiliations

Soon will be listed here.

Abstract

The past years have witnessed the vigorous development of immunotherapy, mainly immune checkpoint inhibitors (ICIs) targeting the programmed cell death-1 (PD-1) protein and its ligand, PD-L1, and cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4). Indeed, ICIs have largely revolutionized the management and improved the prognosis of patients with intermediate and advanced hepatocellular carcinoma (HCC). However, biomarker-based stratification of HCC patients for optimal response to ICI treatment is still of unmet need and again, there exists the necessity to dynamically monitor treatment effect in real-time manner. The role of conventional biomarkers in immunotherapy surveillance is largely limited by spatial and temporal tumor heterogeneity whereas liquid biopsy seems to be promising to circumvent tumor heterogeneity to identify candidate patients who may response to immunotherapy, to dynamically monitor treatment effect and to unveil resistance mechanism. Herein, we provide a thorough review about the potential utility of liquid biopsy in immunotherapy for HCC and discuss its future perspectives.

Citing Articles

Sophisticated roles of tumor microenvironment in resistance to immune checkpoint blockade therapy in hepatocellular carcinoma.

Zhang Y, Ma Y, Ma E, Chen X, Zhang Y, Yin B Cancer Drug Resist. 2025; 8:10.

PMID: 40051497 PMC: 11883234. DOI: 10.20517/cdr.2024.165.

Efficacy and safety of first-line treatments for advanced hepatocellular carcinoma patients: a systematic review and network meta-analysis.

Li J, Yang B, Teng Z, Liu Y, Li D, Qu X Front Immunol. 2024; 15:1430196.

PMID: 39355238 PMC: 11442238. DOI: 10.3389/fimmu.2024.1430196.

Circulating tumor cells: from new biological insights to clinical practice.

Gu X, Wei S, Lv X Signal Transduct Target Ther. 2024; 9(1):226.

PMID: 39218931 PMC: 11366768. DOI: 10.1038/s41392-024-01938-6.

Hub gene identification and immune infiltration analysis in hepatocellular carcinoma: Computational approach.

Pulakuntla S, Singh S, Reddy V In Silico Pharmacol. 2024; 12(1):39.

PMID: 38721057 PMC: 11074094. DOI: 10.1007/s40203-024-00215-2.

Biomarkers and prognostic factors of PD-1/PD-L1 inhibitor-based therapy in patients with advanced hepatocellular carcinoma.

Zhang N, Yang X, Piao M, Xun Z, Wang Y, Ning C Biomark Res. 2024; 12(1):26.

PMID: 38355603 PMC: 10865587. DOI: 10.1186/s40364-023-00535-z.

References

Gao Q, Wang X, Qiu S, Yamato I, Sho M, Nakajima Y . Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma. Clin Cancer Res. 2009; 15(3):971-9. DOI: 10.1158/1078-0432.CCR-08-1608. View

Brown Z, Greten T, Heinrich B . Adjuvant Treatment of Hepatocellular Carcinoma: Prospect of Immunotherapy. Hepatology. 2019; 70(4):1437-1442. DOI: 10.1002/hep.30633. View

Siravegna G, Marsoni S, Siena S, Bardelli A . Integrating liquid biopsies into the management of cancer. Nat Rev Clin Oncol. 2017; 14(9):531-548. DOI: 10.1038/nrclinonc.2017.14. View

Abbosh C, Birkbak N, Swanton C . Early stage NSCLC - challenges to implementing ctDNA-based screening and MRD detection. Nat Rev Clin Oncol. 2018; 15(9):577-586. DOI: 10.1038/s41571-018-0058-3. View

Ling S, Hu Z, Yang Z, Yang F, Li Y, Lin P . Extremely high genetic diversity in a single tumor points to prevalence of non-Darwinian cell evolution. Proc Natl Acad Sci U S A. 2015; 112(47):E6496-505. PMC: 4664355. DOI: 10.1073/pnas.1519556112. View

Amjad W, Kotiah S, Gupta A, Morris M, Liu L, Thuluvath P . Successful Treatment of Disseminated Hepatocellular Carcinoma After Liver Transplantation With Nivolumab. J Clin Exp Hepatol. 2020; 10(2):185-187. PMC: 7067990. DOI: 10.1016/j.jceh.2019.11.009. View

Ng C, Di Costanzo G, Tosti N, Paradiso V, Coto-Llerena M, Roscigno G . Genetic profiling using plasma-derived cell-free DNA in therapy-naïve hepatocellular carcinoma patients: a pilot study. Ann Oncol. 2018; 29(5):1286-1291. DOI: 10.1093/annonc/mdy083. View

Dyhl-Polk A, Mikkelsen M, Ladekarl M, Nielsen D . Clinical Trials of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma. J Clin Med. 2021; 10(12). PMC: 8234948. DOI: 10.3390/jcm10122662. View

Chae Y, Davis A, Agte S, Pan A, Simon N, Iams W . Clinical Implications of Circulating Tumor DNA Tumor Mutational Burden (ctDNA TMB) in Non-Small Cell Lung Cancer. Oncologist. 2019; 24(6):820-828. PMC: 6656496. DOI: 10.1634/theoncologist.2018-0433. View

10.

Del Re M, van Schaik R, Fogli S, Mathijssen R, Cucchiara F, Capuano A . Blood-based PD-L1 analysis in tumor-derived extracellular vesicles: Applications for optimal use of anti-PD-1/PD-L1 axis inhibitors. Biochim Biophys Acta Rev Cancer. 2020; 1875(1):188463. DOI: 10.1016/j.bbcan.2020.188463. View

11.

Chen X, Fang L, Zhu Y, Bao Z, Wang Q, Liu R . Blood tumor mutation burden can predict the clinical response to immune checkpoint inhibitors in advanced non-small cell lung cancer patients. Cancer Immunol Immunother. 2021; 70(12):3513-3524. PMC: 10991091. DOI: 10.1007/s00262-021-02943-2. View

12.

Gharaibeh R, Jobin C . Microbiota and cancer immunotherapy: in search of microbial signals. Gut. 2018; 68(3):385-388. PMC: 6580757. DOI: 10.1136/gutjnl-2018-317220. View

13.

Zheng Y, Wang T, Tu X, Huang Y, Zhang H, Tan D . Gut microbiome affects the response to anti-PD-1 immunotherapy in patients with hepatocellular carcinoma. J Immunother Cancer. 2019; 7(1):193. PMC: 6651993. DOI: 10.1186/s40425-019-0650-9. View

14.

Ravindranathan D, Anne Russler G, Yantorni L, Drusbosky L, Bilen M . Detection of Microsatellite Instability via Circulating Tumor DNA and Response to Immunotherapy in Metastatic Castration-Resistant Prostate Cancer: A Case Series. Case Rep Oncol. 2021; 14(1):190-196. PMC: 7983538. DOI: 10.1159/000512819. View

15.

Howell J, Atkinson S, Pinato D, Knapp S, Ward C, Minisini R . Identification of mutations in circulating cell-free tumour DNA as a biomarker in hepatocellular carcinoma. Eur J Cancer. 2019; 116:56-66. DOI: 10.1016/j.ejca.2019.04.014. View

16.

Calderaro J, Rousseau B, Amaddeo G, Mercey M, Charpy C, Costentin C . Programmed death ligand 1 expression in hepatocellular carcinoma: Relationship With clinical and pathological features. Hepatology. 2016; 64(6):2038-2046. DOI: 10.1002/hep.28710. View

17.

Sun Y, Wang P, Cheng J, Gong Z, Huang A, Zhou K . Postoperative circulating tumor cells: An early predictor of extrahepatic metastases in patients with hepatocellular carcinoma undergoing curative surgical resection. Cancer Cytopathol. 2020; 128(10):733-745. DOI: 10.1002/cncy.22304. View

18.

Li L, Rao X, Wen Z, Ding X, Wang X, Xu W . Implications of driver genes associated with a high tumor mutation burden identified using next-generation sequencing on immunotherapy in hepatocellular carcinoma. Oncol Lett. 2020; 19(4):2739-2748. PMC: 7068659. DOI: 10.3892/ol.2020.11372. View

19.

Xu L, He M, Dai Z, Yu J, Wang J, Li X . Genomic and transcriptional heterogeneity of multifocal hepatocellular carcinoma. Ann Oncol. 2019; 30(6):990-997. PMC: 6594462. DOI: 10.1093/annonc/mdz103. View

20.

Shi G, Wang J, Huang X, Huang X, He Y, Ji Y . Graft Programmed Death Ligand 1 Expression as a Marker for Transplant Rejection Following Anti-Programmed Death 1 Immunotherapy for Recurrent Liver Tumors. Liver Transpl. 2020; 27(3):444-449. DOI: 10.1002/lt.25887. View